Nabriva's pneumonia drug succeeds late-stage study, shares surge

(Reuters) - Nabriva Therapeutics Plc said on Monday its antibiotic to treat adults with a common form of pneumonia met the main goal of a second late-stage study, putting the company on track to file for the drug's approval in the fourth quarter of 2018.